miR-24-3p and Body Mass Index as Type 2 Diabetes Risk Factors in Spanish Women 15 Years after Gestational Diabetes Mellitus Diagnosis.
Jessica Ares-BlancoCarmen LambertManuel Fernández-SanjurjoPaula Morales-SánchezPedro PujantePaola Pinto-HernandezEduardo Iglesias-GutiérrezEdelmiro Menéndez TorreElías Delgado-ÁlvarezPublished in: International journal of molecular sciences (2023)
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance that is diagnosed for the first time during pregnancy. The objective of this study is to know the glucose tolerance status after 15 years of pregnancy in patients diagnosed with gestational diabetes and to assess the long-term effect of GDM on the circulating miRNA profile of these women. To answer these, 30 randomly selected women diagnosed with GDM during 2005-2006 were included in the study, and glucose tolerance was measured using the National Diabetes Data Group criteria. Additionally, four miRNAs (hsa-miR-1-3p, hsa-miR-24-3p, hsa-miR-329-3p, hsa-miR-543) were selected for their analysis in the plasma of women 15 years after the diagnosis of GDM. In our study we discovered that, fifteen years after the diagnosis of GDM, 50% of women have some degree of glucose intolerance directly related to body weight and body mass index during pregnancy. Dysglycemic women also showed a significantly increased level of circulating hsa-miR-24-3p. Thus, we can conclude that initial weight and BMI, together with circulating expression levels of hsa-miR-24-3p, could be good predictors of the future development of dysglycemia in women with a previous diagnosis of GDM.
Keyphrases
- pregnancy outcomes
- body mass index
- polycystic ovary syndrome
- type diabetes
- body weight
- risk factors
- pregnant women
- cardiovascular disease
- cell proliferation
- end stage renal disease
- chronic kidney disease
- physical activity
- insulin resistance
- weight gain
- poor prognosis
- adipose tissue
- long non coding rna
- skeletal muscle
- blood pressure
- machine learning
- blood glucose
- artificial intelligence
- peritoneal dialysis
- patient reported
- drug induced